Download PDF

Register to download the report. Already a member?

 
 
Sign Up

Or

62462 1502285060HCLSReviewMexicoJuly2017.pdf
Energy Boardroom

Roche jumps into epigenetics with deal for Oryzon's leukemia hopeful

07.04.2014 / Fierce Pharma

pRED has struck its first epigenetics deal, with a $500 million-plus potential payoff for Oryzon and its orphan cancer blocker ORY-1001.

LATEST ISSUE

DOWNLOAD

X
Download PDF

First Name:

Last Name:

Company:

Position:

Country:

Email: